Retatrutide
Retatrutide from the Nexus GLP-1 & Metabolic catalog, supplied for controlled in-vitro research workflows.
Ships from the US with tracking.
Catalog active: Catalog pricing is active. Live warehouse counts are not published.
- Lot-specific COA
- HPLC + MS fields
- Batch archived
For in-vitro research use only. Not for human consumption.
Retatrutide differs from earlier metabolic peptides by simultaneously engaging three distinct G-protein-coupled receptors that regulate energy intake, energy expenditure, and glucose homeostasis. Semaglutide targets only GLP-1; tirzepatide targets GIP and GLP-1; retatrutide adds glucagon receptor agonism as the third axis, contributing to increased energy expenditure in published preclinical work.
No sequence is listed in the current catalog record for this product.
- CAS
- 2381089-83-2
- MW
- 4731.33 Da
- Sequence
- Not listed
- Half-life
- Discussed in research notes
- Formula
- C221H342N46O68
- Purity
- 99.49%
- Form
- Lyophilized powder
- Class
- GIP/GLP-1/Glucagon Triple Receptor Agonist
The dossier.
Compound Overview
Within incretin-pathway research, retatrutide is differentiated by simultaneous engagement of three G-protein-coupled receptor systems associated with energy intake, energy expenditure, and glucose homeostasis research. Semaglutide is used as a GLP-1-only comparator; Tirzepatide is used as a GIP/GLP-1 comparator; Retatrutide adds glucagon receptor agonism as a third mechanistic axis studied in published preclinical models.
Structurally, Retatrutide is a 39-residue peptide made by solid-phase synthesis and incorporates three non-coded amino acid modifications: 2-aminoisobutyric acid (Aib) at positions 2 and 20 for DPP-4 resistance, plus α-methyl-leucine (αMeL) at position 13 to optimize GIP receptor activity. A C20 fatty diacid moiety is attached to the lysine residue at position 17 through an AEEA-γGlu linker, supporting albumin binding and an extended pharmacokinetic half-life in research models.
Research Background & Published Literature
Retatrutide is a prominent incretin-family research peptide in recent published pharmacology literature. Jastreboff and colleagues reported phase 2 clinical-study findings for the LY3437943 program, while Coskun et al. described receptor binding, signaling profile, and proof-of-concept pharmacology in preclinical systems. These sources are provided for literature context only and do not change the Nexus research-use-only status of this material.
Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:
Storage, Handling & Stability Guidelines
Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.
- Keep ambient-temperature handling time as short as practical to support compound integrity.
- Reseal vials promptly after each withdrawal to limit moisture exposure.
- Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
- For traceability, label all aliquots with compound name, concentration, reconstitution date, and operator initials.
Quality Assurance & Lab Verification
A finalized public Certificate of Analysis is available for this catalog item. Review the public COA for the applicable lot. Lot-specific identifiers, assay values, and methods are maintained in that record and are not repeated in this product dossier.
Shipping
Orders ship within the United States via USPS; international orders are not accepted. Laboratories should follow their validated SOP together with any handling fields published for the represented product or lot; no universal prepared-solution condition is inferred here.
Compound details.
- CAS Number
- 2381089-83-2
- Molecular Weight
- 4731.33 Da
- Molecular Formula
- C₂₂₁H₃₄₂N₄₆O₆₈
- Class
- GIP/GLP-1/Glucagon Triple Receptor Agonist
Research context.
Retatrutide is one of the most extensively studied incretin-family peptides published in the past five years. Jastreboff and colleagues reported phase 2 clinical-study findings for the LY3437943 program, while earlier discovery and pharmacology data from Coskun et al. (Cell Metabolism, 2022) characterized receptor binding, signaling profile, and proof-of-concept activity in preclinical systems. Nexus cites these sources for literature context only; the catalog record remains research-use-only and does not present therapeutic, body-composition, or human-use guidance.
Verification standard.
Certificate information is lot-specific. A finalized public record shows only the methods, fields, and results present for that named lot. A pending certificate state exposes no assay values and must not be interpreted as analytical verification. Review Nexus lab verification.
Analytical record.
- Reported HPLC purity
- 99.49%
- Retention time
- 17.80 min
- Observed mass
- 4731.50 Da
- Batch
- APX-2026-0428-R
The normalized Certificate of Analysis publishes only the lot-specific fields represented in the public record. It is not an originating laboratory report or raw instrument file.
View certificate of analysis - batch APX-2026-0428-R- Sequence
- Not listed
- Model preview
- Unavailable
Molecular model preview is unavailable for this catalog record.
The chemistry.
Static molecular fallback shown because this catalog record does not include a sequence suitable for the amino-acid viewer.
Related research compounds
Comparable catalog records with published variants and certificate status.
- GLP-1 & MetabolicCertificate pendingRetatrutide 5mg+cagrilintide 5mgPrice$91.99Formats1 size
Compare size options, price, and certificate status before opening the product record.
View product - GLP-1 & MetabolicVerified batchcagrilintidePriceFrom $58.99Formats3 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 1415456-99-3View product - GLP-1 & MetabolicVerified batchTirzepatidePriceFrom $28.99Formats10 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 2023788-19-2View product - GLP-1 & MetabolicVerified batchSemaglutidePriceFrom $14.99Formats6 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 910463-68-2View product - GLP-1 & MetabolicVerified batchMazdutidePriceFrom $94.99Formats2 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 2259884-03-0View product
Retatrutide research FAQ.
What is Retatrutide used for in research?
Retatrutide is supplied for controlled in-vitro research workflows in the GLP-1 & Metabolic category. It is not labeled for human or veterinary use.
Does Retatrutide have a finalized analytical record?
Retatrutide has a finalized Nexus Lab Verified record that reports 99.49% HPLC area-percent purity for the represented batch. Other fields are shown only where present.
Which Retatrutide variants are published?
Published Nexus variants include 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg.
Does Retatrutide include a COA?
Yes. The current Nexus record links Retatrutide to finalized batch APX-2026-0428-R.